Anti-CD4 antibody

摘要

An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell.;The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

主权项

1. A DNA encoding a monoclonal antibody or antibody fragment thereof, wherein said monoclonal antibody or antibody fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein said monoclonal antibody or antibody fragment thereof is selected from the group consisting of (a)-(d):
(a) a monoclonal antibody or antibody fragment thereof in which the VH and VL comprise the amino acid sequences of SEQ ID NOs: 16 and 26, respectively, or the VH and VL comprise the amino acid sequences of SEQ ID NOs: 12 and 22, respectively; (b) a monoclonal antibody or antibody fragment thereof in which CDRs 1 to 3 of the VH comprise the amino acid sequences of SEQ ID NOs: 51 to 53, respectively, and CDRs 1 to 3 of the VL comprise the amino acid sequences of SEQ ID NOs: 54 to 56, respectively; (c) a monoclonal antibody or antibody fragment thereof in which CDRs 1 to 3 of the VH comprise the amino acid sequences of SEQ ID NOs: 27 to 29, respectively, and CDRs 1 to 3 of the VL comprise the amino acid sequences of SEQ ID NOs: 30 to32, respectively; and (d) a monoclonal antibody or antibody fragment thereof selected from the group consisting of (1)-(5):
(1) a humanized antibody in which the VH and VL comprise the amino acid sequences of SEQ ID NOs: 77 and 78, respectively;(2) a humanized antibody in which the VH and VL comprise the amino acid sequences of SEQ ID NOs: 96 and 78, respectively;(3) a humanized antibody in which the VH and VL comprise the amino acid sequences of SEQ ID NOs: 98 and 78, respectively;(4) a humanized antibody in which the VH and VL comprise the amino acid sequences of SEQ ID NOs: 100 and 78, respectively; and(5) a humanized antibody in which the VH and VL comprise the amino acid sequences of SEQ ID NOs: 100 and 102, respectively.